Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi
| Autor: | Peyclit, Lucie, Yousfi, Hanane, Rolain, Jean-Marc, Bittar, Fadi |
|---|---|
| Přispěvatelé: | Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), ANR-10-IAHU-0003,Méditerranée Infection,I.H.U. Méditerranée Infection(2010), European Project, Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
emerging fungi
new targets repositioning [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases drug repurposing yeasts therapeutic alternatives Review Candida auris [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology Aspergillus spp RS1-441 Pharmacy and materia medica [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system multidrug resistance [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology Medicine [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology antifungals |
| Zdroj: | Pharmaceuticals Pharmaceuticals, 2021, 14 (5), pp.488. ⟨10.3390/ph14050488⟩ Pharmaceuticals, Vol 14, Iss 488, p 488 (2021) Pharmaceuticals, MDPI, 2021, 14 (5), pp.488. ⟨10.3390/ph14050488⟩ |
| ISSN: | 1424-8247 |
| DOI: | 10.3390/ph14050488⟩ |
| Popis: | International audience; Immunodepression, whether due to HIV infection or organ transplantation, has increased human vulnerability to fungal infections. These conditions have created an optimal environment for the emergence of opportunistic infections, which is concomitant to the increase in antifungal resistance. The use of conventional antifungal drugs as azoles and polyenes can lead to clinical failure, particularly in immunocompromised individuals. Difficulties related to treating fungal infections combined with the time required to develop new drugs, require urgent consideration of other therapeutic alternatives. Drug repurposing is one of the most promising and rapid solutions that the scientific and medical community can turn to, with low costs and safety advantages. To treat life-threatening resistant fungal infections, drug repurposing has led to the consideration of well-known and potential molecules as a last-line therapy. The aim of this review is to provide a summary of current antifungal compounds and their main resistance mechanisms, following by an overview of the antifungal activity of non-traditional antimicrobial drugs. We provide their eventual mechanisms of action and the synergistic combinations that improve the activity of current antifungal treatments. Finally, we discuss drug repurposing for the main emerging multidrug resistant (MDR) fungus, including the Candida auris, Aspergillus or Cryptococcus species. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|